Docteur GUILLAUME LARID

Thèses universitaires

• Profils cytokiniques du rhumatisme psoriasique

  Aspects moléculaires et cellulaires de la biologie🎓 Poitiers

  Direction : Elisabeth Solau-Gervais

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

  2025

  ArticleJournal of the European Academy of Dermatology and Venereology

• METHOFRACT, a methotrexate osteopathy multicentre cohort study

  2025

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

• Impact of hospital internships on success in university summative objective structured clinical examinations: Large-scale experience in a French medical school

  2024

  ArticlePLoS ONE

• Detection of hypophosphatasia in hospitalised adults in rheumatology and internal medicine departments: a multicentre study over 10 years

  2024

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

• Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

  2024

  ArticleScientific Reports

• Interleukin 34 exerts anti-inflammatory activities on keratinocytes and is down-regulated in psoriatic-inflamed skin

  2023

  ArticleJournal of Investigative Dermatology

• Recommandations alimentaires dans le cadre de la prévention et du traitement de l’ostéoporose

  2023

  ArticleRevue du Rhumatisme

• Dietary Recommendations in the Prevention and Treatment of Osteoporosis

  2023

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CHU LA MILETRIE

  2 Rue DE LA MILETRIE, 86021 Poitiers

  ☎ 0549444444Hospitalier🏥 Centre CHU ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (2)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Rhumatologie : expertise et recherche au CHU de Poitiers - Site du CHU de Poitiers

  📰 Site du CHU de Poitiers · 20/05/2022

  <a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOQk5EdzVTWEswaTVLXzdpYTFCQ2s0U0lZdDJZX3lVeXR1elBoQXhEWlp2WERkY05ob2lEMVBsV1JQRmZubl9wRngyWHlJMFJJLWY1bVB5dUdWVDJYbjlVSS14Y0tzTlQwdDFyc3FiNU5vbTE3MGhQdmItaWt0UlJiSXhBTGtOTzFmbUxF?oc=5" target="_blank">Rhumatologie : expertise et recherche a

• Un voile levé sur les maladies rares - Le7.info

  📰 Le7.info · 18/03/2025

  <a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE93XzlIQVVGYmRuejJVcHkyWjhIOFFoR2t0NnY3MTVoRno1bmcyczdxd2JWaHR3YU1IWVNqdzF0X1dmTkNGaE9acm9rXzBHc0wyVnE0cVVWNGJSV3g3U2tKMElFcEk4cXRTRldkMXZCOGVhX3FJUktkdmFWYw?oc=5" target="_blank">Un voile levé sur les maladies rares</a>&nbsp;&nbsp;<font col

Top publications · les plus citées

• 1

  Dietary recommendations in the prevention and treatment of osteoporosis

  Joint bone spine · 2023

  📚 33 citations🎯 RCR 5.46Top 7% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
• 2

  In Rheumatoid Arthritis Patients, HLA-DRB1*04:01 and Rheumatoid Nodules Are Associated With ACPA to a Particular Fibrin Epitope

  Frontiers in immunology · 2021

  📚 22 citations🎯 RCR 1.72🔓 Open Access

  Lire l'abstract Crossref ↓

  ObjectivesRheumatoid arthritis (RA) is associated with HLA-DRB1 genes encoding the shared epitope (SE), a 5-amino acid motive. RA is usually preceded by the emergence of anti-citrullinated protein/peptide antibodies (ACPAs). Citrulline is a neutral amino acid resulting from post-translational modification of arginine involved in peptidic bounds (arginyl residue) by PeptidylArginine Deiminases (PADs). ACPAs recognize epitopes from citrullinated human fibrin(ogen) (hFib) and can be specifically detected by the AhFibA assay. Five citrullinated peptides derived from hFib together represent almost all of the epitopes recognized by patients with ACPA-positive RA, namely: α36–50cit, α171–185cit, α501–515cit, α621–635cit, and β60–74cit. The use of antibody fine specificities as markers of clinical phenotypes has become a major challenge. Our objective was to study whether RA clinical characteristics and HLA-DRB1 genetic background were associated with a specific reactivity against the epitopes borne by the five peptides.Methods184 ACPA-positive RA patients fulfilling the 2010 ACR/EULAR criteria were studied. Patient characteristics including HLA-DRB1 genotype, were collected from their medical files. Anti-CCP2 antibodies, AhFibA, and antibodies against the five citrullinated hFib (hFib-cit) peptides were analyzed by ELISA.ResultsAnti-α505-515cit antibodies were associated with HLA-DRB1*04:01 (OR = 5.52 [2.00 – 13.64]; p = 0.0003). High level anti-α505-515cit antibodies were associated with rheumatoid nodules (OR = 2.71 [1.00 – 7.16], p= 0.044).ConclusionImmune complexes containing anti-α501-515cit antibodies and rheumatoid factors might be involved in the development of rheumatoid nodules on the HLA-DRB1*04:01 background. Apheresis of these epitope-specific antibodies might be a new therapeutic opportunity for patients with rheumatoid nodules.

• 3

  Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study

  Frontiers in medicine · 2022

  📚 14 citations🎯 RCR 1.93🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectivesPrevious studies demonstrated equivalence in terms of efficacy and safety of biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching situations. Less is known about what happens when initiating a bsDMARD in a molecule naïve patient. The objectives of our study were to compare the retention of treatment of subcutaneous boDMARDs and bsDMARDs globally, depending on the disease [rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic arthritis (PsA)], molecule [etanercept (ETN) or adalimumab (ADA)], line of treatment, or presence of citrate in the context of first use of each molecule (namely initiation) and to analyze treatment retention’s predictive factors.Materials and methodsThis multicenter retrospective study used data from shared medical records of the RIC-FRANCE network, encompassing the prescription of hospital rheumatologists and attached practitioners, of patients with RA, SpA, or PsA, with the starting ETN between 03/10/2016 and 31/07/2020, or ADA between 23/10/2018 and 31/07/2020. Clinical data were collected from medical records. Retention analysis was performed using Kaplan–Meier curves and the log-rank test. Retention’s predictive factors were analyzed using Cox proportional-hazard ratio.ResultsEight hundred forty-five prescriptions were analyzed: 340 boDMARDs and 505 bsDMARDs. About 57% of prescriptions concerned women. The mean age was 51.8 years. About 38% were prescriptions for RA, 16% for PsA, and 46% for SpA. An increase in the initiation over time was observed for both ETN and ADA. The retention rate of bsDMARDs was superior to boDMARDs’ one (39 vs. 23 months; p = 0.045). When molecules are compared, the difference was significant only for ETN (45 vs. 19 months for boDMARD; p = 0.0265). When comparing diseases, the difference in favor of bsDMARDs was significant in patients with RA only (p = 0.041). Citrated treatments displayed better retention compared to citrate-free treatments (p = 0.0137). Multivariable analysis of predictive factors for the cessation of treatment found shorter disease duration, boDMARD prescription, hospital practitioner prescription, late line of treatment, and female sex as significant. More side effects were observed with boDMARDs, especially more infections (17.8% vs. 7.8%).ConclusionEven if bsDMARDs’ prescription increases over time, its penetration rate is still below expectations. bsDMARDs displayed better retention compared to boDMARDs, especially for ETN, and in patients with RA. Citrated treatments had better retention. Prescription by a full-time hospital-based rheumatologist is associated with poorer retention.

Publications scientifiques (21) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche